E-LIB Suche - Ergebnisse für: Steino, A.

1

PO-014 Dianhydrogalactitol (vaL-083) reduces glioblastoma t..:

Golebiewska, A. ; Oudin, A. ; Steino, A....
ESMO Open. 3 (2018) - p. A232-A233 , 2018

2

48 Phase 2 studies of dianhydrogalactitol (VAL-083) in pati..:

Bacha, JA ; Steino, A ; Schwartz, R...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 45 (2018) S3 - p. S10-S10 , 2018

Link: https://doi.org/10.1017/..

3

49 Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor..:

Golebiewska, A ; Oudin, A ; Steino, A...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 45 (2018) S3 - p. S15-S15 , 2018

Link: https://doi.org/10.1017/..

4

P09.57 Clinical trials of VAL-083 in patients with chemores..:

Bacha, J. A. ; Steino, A. ; Schwartz, R....
Neuro-Oncology. 19 (2017) suppl_3 - p. iii83-iii83 , 2017

Link: https://doi.org/10.1093/..

5

P08.57 Distinct mechanism-of-action of dianhydrogalactitol ..:

Zhai, B. ; Gobielewska, A. ; Steino, A....
Neuro-Oncology. 19 (2017) suppl_3 - p. iii66-iii66 , 2017

Link: https://doi.org/10.1093/..

6

Molecular mechanisms of dianhydrogalactitol (VAL-083) in ov..:

Steino, A. ; Zhai, B. ; Daugaard, M....
European Journal of Cancer. 69 (2016) - p. S119 , 2016

Link: https://doi.org/10.1016/..

7

PC3 - 154 Phase I/II Study of VAL-083 in Patients with Recu..:

Shih, K.C. ; Patel, M.R. ; Butowski, N....
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 43 (2016) S4 - p. S18-S18 , 2016

Link: https://doi.org/10.1017/..

8

P08.47 Dianhydrogalactitol (VAL-083) causes bifunctional al..:

Zhai, B. ; Steino, A. ; Bacha, J. A...
Neuro-Oncology. 18 (2016) suppl_4 - p. iv52-iv52 , 2016

Link: https://doi.org/10.1093/..

9

PS2 - 153 Dianhydrogalactitol (VAL-083) Treatment Causes Ir..:

Zhai, B. ; Steino, A. ; Bacha, J...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 43 (2016) S4 - p. S12-S13 , 2016

Link: https://doi.org/10.1017/..

10

PC3 - 155 Phase II Study of Dianhydrogalactitol in Patients..:

O'Brien, B.J. ; Bacha, J.A. ; Brown, D.M....
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 43 (2016) S4 - p. S18-S18 , 2016

Link: https://doi.org/10.1017/..

11

AT-53 * PHASE I/II STUDY OF DIANHYDROGALACTITOL IN PATIENTS..:

Shih, K. ; Patel, M. ; Butowski, N....
Neuro-Oncology. 16 (2014) suppl 5 - p. v20-v20 , 2014

Link: https://doi.org/10.1093/..

12

ET-18 * VAL-083 IS A NOVEL N7 ALKYLATING AGENT THAT INHIBIT..:

Fouse, S. ; Steino, A. ; Butowski, N....
Neuro-Oncology. 16 (2014) suppl 5 - p. v83-v83 , 2014

Link: https://doi.org/10.1093/..

13

Interaction of C1q with the Receptor Calreticulin Requires ..:

Steinø, A. ; Jørgensen, C. S. ; Laursen, I..
Scandinavian Journal of Immunology. 59 (2004) 5 - p. 485-495 , 2004

Link: https://doi.org/10.1111/..

14

CTNI-26. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN ..:

O'Brien, Barbara ; Penas-Prado, Marta ; Kamiya-Matsuoka, Carlos...
Neuro-Oncology. 23 (2021) Supplement_6 - p. vi65-vi65 , 2021

Link: https://doi.org/10.1093/..

15

Proteomic Screens for Suppressors of Anoikis Identify IL1RA..:

Zhang, Hai-Feng ; Hughes, Christopher S. ; Li, Wei...
Cancer Discovery. 11 (2021) 11 - p. 2884-2903 , 2021

Link: https://doi.org/10.1158/..